. "RIV/61988987:17110/14:A1501CGB!RIV15-MSM-17110___" . "55" . "RIV/61988987:17110/14:A1501CGB" . "Lewis, Philip" . "Delforge, Michel" . . . . "7" . "Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial" . . . "17110" . "Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial"@en . . "Dimopoulos, Meletios A." . . . "Zhang, Jingshan" . . "Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial" . "1"^^ . "[0D863C74AA14]" . "H\u00E1jek, Roman" . "In the MM-015 trial, melphalan - prednisone - lenalidomide followed by lenalidomide maintenance (MPR-R) signifcantly prolonged progression-free survival versus melphalan - prednisone (MP) in newly diagnosed patients with multiple myeloma aged >= 65 years. Health-related quality of life (HRQoL), a secondary endpoint of MM-015, was also improved with MPR-R. This sub-analysis evaluated the impact of individual predictive factors on HRQoL. Patients completed HRQoL questionnaires at baseline, every third cycle and at progressive disease (PD)/treatment discontinuation." . "Mei, Jay" . . . "Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial"@en . "9"^^ . . "1042-8194" . "Millar, Stefanie" . "16365" . "In the MM-015 trial, melphalan - prednisone - lenalidomide followed by lenalidomide maintenance (MPR-R) signifcantly prolonged progression-free survival versus melphalan - prednisone (MP) in newly diagnosed patients with multiple myeloma aged >= 65 years. Health-related quality of life (HRQoL), a secondary endpoint of MM-015, was also improved with MPR-R. This sub-analysis evaluated the impact of individual predictive factors on HRQoL. Patients completed HRQoL questionnaires at baseline, every third cycle and at progressive disease (PD)/treatment discontinuation."@en . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . . . . "10"^^ . "Health-related quality of life (HRQoL); lenalidomide; multiple myeloma; minimal important difference (MID); QLQ-C30; QLQ-MY20"@en . "Palumbo, Antonio" . "I" . "Kropff, Martin" . . "Petrucci, Maria Teresa" . "Leukemia & Lymphoma" .